Results 221 to 230 of about 55,766 (252)
Some of the next articles are maybe not open access.
Mechanisms of fluoroquinolone resistance
Drug Resistance Updates, 1999Mechanisms of bacterial resistance to fluoroquinolones fall into two principal categories, alterations in drug target enzymes and alterations that limit permeation of drug to the target, both resulting from chromosomal mutations. No specific resistance mechanisms of quinolone degradation or modification have been found.
openaire +2 more sources
Streptococcus pneumoniae resistance to fluoroquinolones
The Lancet, 19961 Child J, Andrews J, Boswell F, Brenwald NP, Wise R. The in vitro activity of CP 99,219, a new naphthyridone antimicrobial agent. J Antimicrob Chemother 1995; 35: 869–76. 2 Petersen U, Bremm KD, Dalhoff A, et al. Synthesis in BAY 12-8039, a new 8-methoxy-quinolone. Abst no F1.
R, Wise, N, Brenwald, M, Gill, A, Fraise
openaire +2 more sources
Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage [PDF]
International Journal of Medical Microbiology, 2011 We investigated the usage of fluoroquinolones and the prevalence of fluoroquinolone resistant pneumococci and their precursors (first step mutants and efflux expressing isolates) in patients with community-acquired pneumonia, who were enroled into the ...
Mathias W Pletz +2 more
exaly +2 more sources
Resistance to Ciprofloxacin and the New Fluoroquinolones
Journal of Chemotherapy, 2000Resistance to ciprofloxacin has generally remained low in the UK. A low rate of resistance development in vitro has been suggested for the newer fluoroquinolones such as grepafloxacin and trovafloxacin. Levofloxacin is likely to have a pattern of development of resistance similar to that of ofloxacin.
openaire +2 more sources
Fluoroquinolones: mechanisms of action and resistance
International Journal of Antimicrobial Agents, 1993The mechanism of action and the mechanism of resistance of the 4-quinolones are complex and poorly understood. The first barrier these molecules must cross is the bacterial outer membrane. In gram-negative species, 4-quinolones pass through either the porins or lipopolysaccharides (or both) depending on their chemical nature. The cellular target is the
openaire +2 more sources
Journal of Chemotherapy, 2003
The bactericidal activity of levofloxacin, ciprofloxacin, moxifloxacin and norfloxacin against clinical isolates conventionally classified as resistant to fluoroquinolones were compared at their maximum concentrations in serum, urine (except moxifloxacin) and bronchial mucosa (except norfloxacin).
L. Drago +5 more
openaire +2 more sources
The bactericidal activity of levofloxacin, ciprofloxacin, moxifloxacin and norfloxacin against clinical isolates conventionally classified as resistant to fluoroquinolones were compared at their maximum concentrations in serum, urine (except moxifloxacin) and bronchial mucosa (except norfloxacin).
L. Drago +5 more
openaire +2 more sources
Fluoroquinolone Resistance in Bacteria
2009FQs are some of the most widely prescribed antimicrobial agents. Of the total sales of $42 billion from antibiotics worldwide in 2009, FQs represented 17 % of the market, generating $7 billion in global sales (Furiex Pharmaceuticals; http://www.furiex.com).
Varsha V. Moudgal, Glenn W. Kaatz
openaire +1 more source
Mechanisms of Resistance to Fluoroquinolones
1998In the early 1980s, when fluoroquinolones were an area of rapid development and considerable pharmaceutical company interest, it was commonly believed that resistance to fluoroquinolones would not become a problem, as it had with previous classes of antibiotics, as fluoroquinolone-resistant Escherichia coli could only be selected with great difficulty ...
M. J. Everett, L. J. V. Piddock
openaire +1 more source
Emerging Resistance to Fluoroquinolones in Staphylococci: An Alert
Annals of Internal Medicine, 1991The fluoroquinolones are orally administered antimicrobial agents introduced in the mid-1980s. Although they are particularly effective for treating gram-negative bacillary infections, some agents,...
M, Trucksis, D C, Hooper, J S, Wolfson
openaire +2 more sources
Survey of Ophthalmology, 2004
The three topical ophthalmic fluoroquinolones recently introduced into the U.S. market--levofloxacin, gatifloxacin, and moxifloxacin--offer several advantages over the previously available fluoroquinolones (norfloxacin 0.3%, ciprofloxacin 0.3%, and ofloxacin 0.3%).
openaire +2 more sources
The three topical ophthalmic fluoroquinolones recently introduced into the U.S. market--levofloxacin, gatifloxacin, and moxifloxacin--offer several advantages over the previously available fluoroquinolones (norfloxacin 0.3%, ciprofloxacin 0.3%, and ofloxacin 0.3%).
openaire +2 more sources